Using genotype data to perform accurate genetic prediction of complex traits can 20 facilitate genomic selection in animal and plant breeding programs, and can aid in the 21 development of personalized medicine in humans. Because most complex traits have a 22 polygenic architecture, accurate genetic prediction often requires modeling all genetic 23 variants together via polygenic methods. Here, we develop such a polygenic method, 24 which we refer to as the latent Dirichlet process regression model (DPR). DPR is non-25 parametric in nature, relies on the Dirichlet process to flexibly and adaptively model the 26 effect size distribution, and thus enjoys robust prediction performance across a broad 27 spectrum of genetic architectures. We compare DPR with several commonly used 28 prediction methods with simulations. We further apply DPR to predict gene expressions, 29 to conduct PrediXcan based gene set test, to perform genomic selection of four traits in 30 two species, and to predict eight complex traits in a human cohort. 31 32 33 34 35 3/43 accurate phenotype and risk prediction. Instead, accurate phenotype prediction requires 63 polygenic models that can make use of all genome-wide SNPs 9,18-20 . In the past decade, 64 successful development and application of many polygenic models in the context of 65 genomic selection has revolutionized many animal breeding programs 16,21-23 . More 66 4/43 recently, applications of polygenic models to human GWASs have also yielded fruitful 67 results 11,24-27 . 68 Most existing polygenic models for prediction make an assumption on the effect size 69 distribution and different methods differ mainly in such modeling assumption. For 70 example, the commonly used linear mixed model (LMM), also known as the best linear 71 unbiased predictor (BLUP), assumes that the effect sizes from all variants follow a 72 normal distribution 9,28 . The Bayes alphabetic (e.g. BayesA and BayesB) methods assume 73 that the variant effect sizes follow a t-distribution or its variation 10,18,29 . The Bayesian 74 lasso assumes a double exponential/Laplace distribution 30,31 . NEG generalizes the 75 Bayesian lasso by assuming a normal exponential gamma distribution 32 . BVSR and 76
Introduction 36
Genome-wide association studies (GWASs) have identified thousands of genetic loci 37 harboring associated single nucleotide polymorphisms (SNPs) for many complex traits 38 and diseases, providing unprecedented insights into the genetic basis of phenotypic 39 variation 1-8 . The accumulation of genetic data from existing association studies has led to 40 a growing interest in predicting traits and diseases using genetic markers (in addition to 41 using traditional environmental or clinical variables) 9 . In animals or plants, accurate 42 phenotype prediction with genetic markers can assist the selection of individuals with 43 desirable breeding values and can improve the effectiveness of breeding programs 10 . In 44 humans, accurate phenotype prediction with genetic markers can facilitate disease 45 prevention and intervention at early stages and can aid in the development of 46 personalized medicine by using genotype information to customize the treatment and 47 predict the outcome 11 . Phenotype prediction has also been proposed recently as a key 48 step for integrating functional genomic sequencing studies with GWASs: we can 49 construct more powerful and interpretable gene-set tests in GWASs by setting variant 50 weights to be the coefficients inferred from predictive models in expression quantitative 51 trait locus (eQTL) mapping studies 12 . 52
Progress towards accurate phenotype prediction requires the development of statistical 53 methods that can model all SNPs jointly. Previous association studies have demonstrated 54 that most complex traits and common diseases have a polygenic background and are each 55 influenced by many genetic variants with small effects. For instance, it is estimated that 56 thousands of causal variants influence human height 13 . Similarly, many animal or plant 57 traits are contributed by hundreds of causal variants (e.g. maize-related traits, such as 58 kernel oil and growing degree days 14, 15 ; and cattle-related traits, such as backfat thickness, 59 milk yield and hot carcass weight 16, 17 ). Because most complex traits and common 60 diseases have a polygenic architecture, a handful of identified associated SNPs often only 61 capture a small proportion of the phenotypic variation and thus cannot be used to yield 62 Results 117 Method overview. An overview of our method is provided in the Methods section with 118 details provided in the Supplementary Note. Briefly, we use a Dirichlet process to 119 introduce a non-parametric effect size distribution that can robustly resemble a large 120 classes of unimodal distributions. Indeed, our prior effect size distribution can be used to 121 adaptively and accurately approximate a t-distribution, a point-t mixture distribution, a 122 mixture of step functions, as well as the marginal effect sizes estimated from a real data 123 set; whereas a normal distribution cannot (Fig. 1) . Therefore, our prior distribution on the 124 effect size can adaptively approximate a wide range of possible effect size distributions 125 underlying complex traits. Since accurate modeling of the effect size distribution is a key 126 to achieve accurate prediction performance 24,34,36 , we expect our non-parametric model to 127 perform robustly well across a range of polygenic architectures. Our method is 128 implemented in the DPR software, freely available at http://www.xzlab.org/software.html. 129
Simulations. We first compare the performance of DPR with several other commonly 130 used prediction methods using simulations. A total of seven different methods are 131 To make our simulations as real as possible, we used genotypes from an existing 138 cattle GWAS dataset 17 with 5,024 individuals and 42,551 SNPs and simulated 139 phenotypes. To cover a range of possible genetic architectures, we consider eight 140 simulation settings from four different simulation scenarios with the phenotypic variance 141 explained (PVE) by all SNPs being either 0.2, 0.5, or 0.8 (details in Methods). In each 142 setting for each PVE value, we performed 20 simulation replicates. In each replicate, we 143 randomly split the data into a training data with 80% individuals and a test data with the 144 7/43 remaining 20% individuals. We then fitted different methods on the training data and 145 evaluated their prediction performance on the test data (i.e. Monte Carlo cross validation). 146
We evaluated prediction performance using either the squared correlation coefficient (R 2 ) 147 or mean squared error (MSE). We contrasted the prediction performance of all other 148 methods with that of DPR.MCMC by taking the difference of R 2 or MSE between the 149 other methods and DPR.MCMC. Therefore, an R 2 difference below zero or an MSE 150 difference above zero suggests worse performance than DPR.MCMC. Fig. 2 shows R 2 151 differences for different methods across 20 replicates in each of the eight simulation 152 settings for PVE=0.5. Because Fig. 2 shows prediction performance difference, a large 153 sample variance of a method in the figure only implies that the prediction performance of 154 the method differs a lot from that of DPR.MCMC, but does not imply that the method 155 itself has a large variation in predictive performance. Supplementary Table 1 Overall, while each method works the best when their individual modeling 162 assumption is satisfied, DPR.MCMC is robust and works well across all eight settings 163 from four scenarios. For example, if we rank the methods based on their median 164 performance across replicates, then when the total PVE is moderate (e.g. PVE=0.5, Fig. 2 ; 165 note that for each PVE there are a total of eight simulation settings for the four scenarios), 166 DPR.MCMC is the best or among the best in seven simulation settings (i.e. scenario I, 167 c=10, 100 and 1,000 in scenario III, and normal, t and Laplace distributions in scenario 168 IV; where "among the best" refers to the case when the difference between the given 169 method and the best method is within ±0.001) and is ranked as the second best in the rest 170 one simulation setting (i.e. scenario II). Similarly, when the total PVE is high (e.g. 171 PVE=0.8, Supplementary Fig. 2 ), DPR.MCMC is the best or among the best in seven 172 simulation settings, and it is ranked as the second best in scenario IV when the effect size 173 follows a normal distribution. Even when DPR.MCMC is ranked as the second best 174 method, the difference between DPR.MCMC and the best method is often small. Among 175 8/43 the rest of the methods, LMM, MultiBLUP and rjMCMC all work well in polygenic 176 settings (scenario I; c=1,000 in scenario III; scenario IV) but can perform poorly in 177 sparse settings (scenario II; c=10 and c=100 in scenario III). The performance of LMM, 178
MultiBLUP and rjMCMC in polygenic vs sparse settings presumably stems from their 179 polygenic assumptions on the effect size distribution. In contrast, because of the sparse 180 assumption on the effect size distribution, both BayesR and BVSR have an advantage in 181 sparse settings (scenario II; c=10 or 100 in scenario III) but suffers in polygenic settings 182 (c=1,000 in scenario III; scenario IV). The performance of BVSR is also generally worse 183 than BayesR in the challenging setting when PVE is either small or moderate, 184 presumably because of the much simpler prior assumption employed in BVSR for the 185 non-zero effects. Finally, the VB version of DPR (i.e. DPR.VB) performs considerably 186 less well compared with the MCMC version of DPR (i.e. DPR.MCMC), especially when 187 PVE is high ( Supplementary Fig. 2 ). However, DPR.VB still compares favorably with 188 the other methods when PVE is small or moderate ( Supplementary Fig. 1 ). 189
Real data applications. To gain further insights, we compare the performance of DPR 190 with the other methods in several real data sets to (1) predict gene expression levels using 191 cis-SNPs; (2) conduct subsequent PrediXcan based gene set test; (3) perform genomic 192 selection in animal studies; and (4) predict complex traits in humans. 193
Our first application is predicting gene expression levels using cis-SNPs in the 194 GEUVADIS data 42 . The GEUVADIS data contains gene expression measurements on 195 15,810 genes and 465 individuals after quality control (Methods). These individuals have 196 their genotypes measured in the 1000 Genomes project 43 . In the data, we first identified 197 cis-SNPs that are within 100 kb of each gene and obtained an average of 175 cis-SNPs 198 per gene. Then, for each gene in turn, we applied different methods to predict gene 199 expression levels using these cis-SNPs. To measure prediction performance, we carried 200 out 20 Monte Carlo cross validation data splits as in simulations. In each data split, we 201 fitted methods in a training set with 80% of randomly selected individuals and evaluated 202 method performance using R 2 in the test set with the remaining 20% of individuals. In 203 addition to the seven methods used in the simulations (i.e. LMM, BVSR, MultiBLUP, 204 9/43 BayesR, rjMCMC, DPR.VB and DPR.MCMC), we also applied Elastic Net (ENET) 44 , 205 which is the default method used in the original PrediXcan paper 12 . Table 1 lists the  206 number of genes with a predictive R 2 above different thresholds for different methods. 207
The predictive R 2 obtained from DPR.MCMC versus various other methods across all 208 genes is shown as scatter plots in Supplementary Fig. 6 , where each plot also lists the 209 number of genes for which DPR.MCMC performs better and the number of genes for 210 which DPR.MCMC performs worse. 211
The results are largely consistent with these in simulations. Overall, DPR.MCMC 212 generally achieves better predictive performance than the other methods. For example, 213 DPR.MCMC is able to achieve a higher predictive R 2 >0.10 in ~1,300 genes, which is 214 ~100 more than that by the second best method at this threshold (i.e. LMM; Table 1 ). 215
Similarly, compared with other methods, not only does DPR.MCMC achieve a higher R 2 216 for most genes; the R 2 improvement from DPR.MCMC can be large for many genes 217 ( Supplementary Fig. 6 ). Among the rest of the methods, the performance of LMM, 218 DPR.VB and ENET are comparable with each other and are ranked right behind 219 DPR.MCMC. On the other hand, the two sparse models (i.e. BVSR and BayesR) 220 perform poorly in this data, especially for some genes whose expression levels are highly 221 predictive by the other methods (Table 1 , Supplementary Fig. 6 ). 222
The robust performance of DPR.MCMC in predicting gene expression levels also 223 translates to a relatively high power in the subsequent PrediXcan gene set test. To 224 perform PrediXcan gene set test, we consider the seven common diseases from WTCCC 4 225 as in Gamazon et al. 12 . For each disease and each gene in turn, we used the estimated cis-226 SNP effect sizes on expression levels from GEUVADIS as weights to construct gene set 227 tests in WTCCC. Following Gamazon et al. 12 , we focused on a set of 4,343 genes that 228 had a predictive R 2 above 0.01 from all methods. The results are shown in Table 2 , which 229 lists the number of significant genes identified by different methods for different diseases. 230
In total, DPR.MCMC identified 38 genes associated with different phenotypes, more 231 than that identified by any other methods. The performance of DPR.MCMC is followed 232 by DPR.VB and subsequently LMM and rjMCMC. Supplementary Table 2 lists the 233 significant genes identified by DPR.MCMC, which are all consistent with previous 234 studies. We also note that, in general, a higher gene expression predictive performance 235 10/43 leads to a higher power in the subsequent gene set analysis. In addition, consistent with 236 their relatively poor gene expression prediction performance, the two sparse models 237 (BayesR and BVSR) do not perform well in the gene set test as well. 238
Finally, we compare the performance of DPR with the other methods in predicting 239 phenotypes in three GWAS data sets: (1) a cattle study 17 , where we focus on three 240 phenotypes: milk fat percentage (MFP), milk yield (MY), as well as somatic cell score 241 (SCS); (2) a maize study 15 , where we use growing degree day (GDD) as the phenotype; 242
(3) the Framingham heart study (FHS) data 45 , where we focus on five plasma traits that 243 include low-density lipoprotein (LDL) cholesterol, glucose (GLU), high-density 244 lipoprotein (HDL) cholesterol, total cholesterol (TC) and triglycerides (TG), and three 245 anthropometric traits that include height, weight and body mass index (BMI). As in 246 simulations, for each phenotype, we performed 20 Monte Carlo cross validation data 247 splits. In each data split, we fitted methods in a training set with 80% of randomly 248 selected individuals and evaluated method performance using R 2 or MSE in a test set 249 with the remaining 20% of individuals. We again contrasted the performance of the other 250 methods with that of DPR.MCMC by taking the R 2 difference or MSE difference with 251 respect to DPR.MCMC. The results are shown in Fig SNPs, SCS is a highly polygenic trait influenced by many SNPs with small effects. 267 BVSR performs poorly for these three traits in the cattle data. In the maize data ( Fig. 3A) , 268 DPR.MCMC performs the best, followed by BayesR, suggesting that GDD is influenced 269 by a few SNPs with large effects 15 . In the Framingham heart study data ( Fig. 3B and Fig.  270 3C), DPR.MCMC performs the best or among the best for LDL, GLU, TC, Weight and 271 BMI. Its performance is comparable to BayesR and rjMCMC for Height, and follows 272 right behind BayesR for HDL and TG. Besides DPR and BayesR, rjMCMC also 273 performs well in FHS and is often ranked as the third best method (e.g. for LDL, GLU, 274
Height and Weight). In contrast to the relatively robust performance of DPR.MCMC, 275 however, all other methods can perform poorly for certain phenotypes. In Fig. 3 , for 276 example, BayesR is the second worst method for predicting GLU; LMM is the second 277 worst method for predicting LDL; MultiBLUP is the worst method for predicting Weight 278 and BMI; DPR.VB performs among the worst for LDL and HDL; rjMCMC performs 279 poorly for HDL; while BVSR performs the worst for almost all traits except for LDL, 280
Height and Weight. The poor performance of BVSR presumably stems from its relatively 281 simple and sparse assumption on the effect sizes. 282
Because the FHS is a family based study, we use this data to further examine the 283 influence of individual relatedness on prediction performance. To do so, we divided the 284 FHS data into two sub data sets (D1 and D2) with equal sample size but different levels 285 of relatedness (details in Methods): individuals in D1 are more closely related to each 286 other than those in D2. We then compared method performance by performing cross 287 validation in each of the two data sets separately. While the difference between methods 288 becomes smaller due to smaller sample size in the two sub data sets, the relative 289 performance of most methods for the eight traits are largely unchanged in these two sub 290 data sets as compared to that in the complete data ( Fig. 9 vs Figs 3B and 3C). For 291 example, DPR.MCMC is ranked as the best method or among the best methods for six 292 traits in D1 and for four traits in D2. BayesR performs similarly and is ranked as the best 293 or among the best for four traits in D1 and for five traits in D2. LMM ranks right after 294 DPR.MCMC and BayesR, while the other methods do not perform well here. In addition, 295 all methods generally perform better in D1 than in D2 ( Supplementary Fig. 10) , 296 suggesting that relatedness improves prediction performance --a phenomenon that has 297 12/43 been well recognized by previous studies 9,23,47-49 . Besides cross validation within each 298 data set separately, we also performed cross validation between D1 and D2 by predicting 299 traits in one data with parameters inferred from another. The results are again largely 300 consistent with the main results. In particular, DPR.MCMC is ranked as the best or 301 among the best for six traits in D1 to D2 prediction and for eight traits in D2 to D1 302 prediction. BayesR is ranked as the best or among the best for six traits in D1 to D2 303 prediction and for eight traits in D2 to D1 prediction. rjMCMC also performs reasonably 304 well and follows right behind DPR.MCMC and BayesR ( Supplementary Fig. 11 ). 305
Computational time. Finally, we list the computational time of the seven methods for 306 the twelve traits in Table 3 . Note that some differences in computational time among 307 methods may reflect implementation issues, including the language environment in 308 which the methods are implemented, rather than fundamental differences between 309 algorithms. In addition, we only list in the We have presented a novel statistical method, DPR, for genetic prediction of complex 328 traits. DPR uses an infinitely many parameters a priori to flexibly model the effect size 329 distribution, and represents the first non-parametric method developed for modeling 330 polygenic traits in genetic association studies. By flexibly modeling the effect size 331 distribution, DPR is capable of adapting to the polygenic architecture underlying many 332 complex traits and enjoys robust performance across a range of phenotypes. With 333 simulations and applications to four real data sets, we have illustrated the benefits of 334
DPR. 335
We have focused on one application of DPR --genetic prediction of phenotypes. 336
Like some other polygenic methods 34,35,50 , DPR can also be applied to many other 337 polygenic applications. For example, DPR can be used to estimate the proportion of 338 variance in phenotypes explained by all SNPs, a quantity that is commonly referred to as 339 SNP heritability 28, 34 . Because DPR assumes a flexible effect size distribution that is 340 adaptive to the genetic architecture underlying a given trait, it has the potential to provide 341 accurate estimation of SNP heritability. As another example, DPR can be applied to 342 association mapping. There, we can view the normal component with the smallest 343 variance as the polygenic background, and we can estimate the probability of a SNP 344 being in any normal components other than the smallest one as the posterior inclusion 345 probability (PIP DPR could be used to perform differential expression analysis 52 or expression QTL 361 mapping in RNA sequencing studies 53, 54 . Similarly, by modeling proportional data, DPR 362 could be used to perform differential methylation analysis or methyl-QTL mapping in 363 bisulfite sequencing studies 55 . Extending DPR to modeling discrete data types using the 364 generalized linear model framework is thus an important avenue for future research. 365
In the present study, while we used unrelated individuals for GEUVADIS gene 366 expression prediction and PrediXcan tests, we used related individuals for the other two We have attempted to tease apart the influence of relatedness on prediction performance 381 by splitting the FHS data into two parts with different levels of relatedness. Our results 382 indeed show that, while the relative performance of various methods remains largely the 383 same, the absolute performance of all methods do increase with individual relatedness. 384
Additionally, while our method performs well relative to the other methods, we caution 385 that DPR's prediction accuracy is still unlikely of practical use in human clinical setting. 386 Studies on unrelated individuals or studies using a fully independent validation data are 387 likely required to establish the practical utility of prediction methods, which often have 388 unsatisfactory performance there 9,47,57 . Despite the practical importance of using 389 15/43 completely independent or cross-population studies for prediction performance validation, 390 however, we also want to point out its potential caveat: using completely independent 391 data for cross-validation may fail to correctly characterize the relative performance of 392 different methods. In particular, a good method that properly captures the signal in the 393 training data may suffer in the validation data due to different LD patterns between the 394 two data sets. Similarly, a poor method that fails to capture the signal in the training data 395 may perform well in the validation data where such signal is no longer relevant. 396 Therefore, using training and validating data that are both representative of the study 397 population is important to not only ensure a proper comparison among methods but also 398 to ensure the clinical relevance and wide applicability of the prediction methods. 399
Exploring the use of such data is an important direction for future research. 400 DPR is not without its limitations. Perhaps the biggest limitation is its computational 401 cost. Like any other MCMC based approaches 34,35,58 , our Gibbs algorithm for fitting DPR 402 is computationally slow and can only be applied to moderate-sized GWAS studies. To 403 make DPR widely applicable, we have explored the use of variational Bayesian 404 approximation for fitting DPR. Variational Bayesian approximation obtains an 405 approximate posterior distribution through optimization 59 and represents a much faster 406 alternative to MCMC sampling. Indeed, DPR.VB is orders of magnitude faster than 407 DPR.MCMC. However, despite its faster computational speed, the VB algorithm is less 408 accurate than MCMC when SNP heritability is large, sometimes by quite a large margin 409 (e.g. PVE=0.80 in simulations). The loss of accuracy in VB is not unexpected because 410 our VB assumes that the posterior distributions of the SNP effect sizes are independent 411 from each other. Posterior independence is an unrealistic assumption given that SNP 412 genotypes are correlated through LD. Therefore, it is important to explore alternative VB 413 algorithms to incorporate the posterior correlation among effect sizes, by, for example, 414 adapting algorithms developed elsewhere 60,61 . It would be ideal if we could develop 415 algorithms that can achieve a high predictive performance as DPR.MCMC but incurs a 416 small computational cost as DPR.VB. Certainly, besides developing alternative 417 algorithms to MCMC, there is still room for improvement on our MCMC algorithm. For 418 example, we could use all individuals to compute some quantities while use only a subset 419 of individuals to compute other quantities, as in our previous MQS method 62 , in order to 420 reduce the computational burden while maintaining the accuracy of the algorithm. In any 421 16/43 case, developing efficient and accurate algorithms likely represents a key step to adapt 422 existing polygenic methods to association studies that are orders of magnitude larger. 423 424 17/43
Methods

425
Overview of DPR. We provide a brief overview of DPR here. Detailed methods and 426 algorithms are provided in the Supplementary Note. To model the relationship between 427 phenotypes and genotypes, we consider the following multiple regression model 428
where y is an n-vector of phenotypes measured on n individuals; W is an n by c matrix of 429 covariates including a column of 1s for the intercept term; Like many previous methods 9,19,28,34,41 , we assume that the effect size of ith SNP, 
where H is the base distribution, and λ is the concentration parameter that describes how 468 the distribution on normal distribution cannot (Fig. 1) . Therefore, our prior distribution on the effect size can 480 adaptively approximate a wide range of possible effect size distributions underlying 481 19/43 complex traits. Since accurate modeling of the effect size distribution is a key to achieve 482 accurate prediction performance 24,34,36 , we expect our non-parametric model to perform 483 robustly well across a range of polygenic architectures. 484
It is important to point out that our modeling assumption on the effect sizes ߚ is also 485 mathematically equivalent to a Dirichlet process normal mixture, which is a mixture of 486 normal distributions with infinitely many normal components. Specifically, using the 487 stick-breaking constructive representation of the Dirichlet process 59 , we can re-write our 488 modeling assumption on ߚ in an equivalent form as 489
where λ is the same concentration parameter as in equation (2), and determines the 490 number of normal components in the model and subsequently the model complexity 59 . 491 Each ߪ ଶ in the above equation follows the base distribution H. From the normal mixture 492 equivalence aspect, our method effectively generalizes many previous methods 18,34,35 that 493 use a fixed, often small, number of normal components to using infinitely many normal 494 components a priori. Although the prior number of normal components in our model is 495 infinite, the posterior number of components for any given data set will be finite, and can 496 be automatically inferred based on the data at hand. Therefore, our model has the 497 potential to adjust the model complexity according to the data complexity, and has the 498 potential to adapt to a wide range of polygenic architectures. 499 To fit our model, we develop two complementary algorithms: one is based on the 500 MCMC algorithm, and the other is based on the variational Bayesian (VB) 501 approximation. The MCMC sampling algorithm, which we refer to as DPR.MCMC, is 502 accurate but computationally slow. The variational Bayesian algorithm, which we refer 503 to as DPR.VB, is computationally fast, but, as we will show in the results, is often less 504 accurate. The two algorithms provide users the choice of speed vs accuracy. The details 505 of the two algorithms are provided in Supplementary Note. 506 20/43
Simulations. we used genotypes from an existing cattle GWAS dataset 17 with 5,024 507 individuals and 42,551 SNPs and simulated phenotypes. To cover a range of possible 508 genetic architectures, we consider eight simulation settings from four different simulation 509 scenarios to cover a range of possible genetic architectures: 510
(1) Scenario I satisfies the DPR modeling assumption, where all SNPs are causal and 511
SNPs in different effect-size groups have different effects. Specifically, we 512 randomly selected 10 group-one SNPs, 100 group-two SNPs, 1,000 group-three 513 SNPs, and set the remaining SNPs as group-four SNPs. We simulated SNP effect 514 sizes all from a standard normal distribution but scaled their effects in each group 515 separately so that the proportion of genetic variance explained by the four groups 516 are 0.05, 0.15, 0.20, and 0.60, respectively. We set the total proportion of 517 phenotypic variance (PVE; i.e. SNP heritability) to be either 0.2, 0.5 or 0.8, 518
representing low, moderate, and high heritability, respectively. This simulation 519 scenario consists of one simulation setting for each PVE. 520
(2) Scenario II satisfies the BayesR modeling assumption, where a small proportion 521 of SNPs are causal. These causal SNPs come from three effect-size groups. The 522 simulations were similar to scenario I with the only exception that the group-four 523 SNPs have zero effects. Here, the proportion of PVE by the three groups are 0.1, 524 0.2, and 0.7, respectively. Again, we set the total PVE to be either 0.2, 0.5 or 0.8. 525
This simulation scenario consists of one simulation setting for each PVE. 526
(3) Scenario III is similar to Scenario I except that SNPs come from two effect-size 527 groups, thus representing a simpler scenario than I. In particular, we selected 528 either c=10, 100 or 1,000 SNPs as group-one SNPs and set the remaining SNPs 529 as group-two SNPs. We simulated their effect sizes from a standard normal 530 distribution and scaled their effects in each group separately so that the proportion 531 of PVE by the two groups are 0.2 and 0.8, respectively. Again, we set the total 532 PVE to be either 0.2, 0.5 or 0.8. This simulation scenario consists of three 533 simulation settings for each PVE (c=10, 100 or 1,000). 534 (4) Scenario IV is related to the assumption made in LMM and MultiBLUP. Here, all 535
SNPs have non-zero effects and their effect sizes come from either a normal 536 distribution, a t-distribution with four degrees of freedom, or a Laplace 537 21/43 distribution. We scaled their effect sizes further so that the total PVE equals 0.2, 538 0.5, or 0.8. This simulation scenario consists of three simulation settings for each 539 PVE (normal, t, or Laplace). 540
In each setting, we performed 20 simulation replicates. In each replicate, we randomly 541 split the data into a training data with 80% individuals and a test data with the remaining 542 20% individuals. We then fitted different methods on the training data and evaluated 543 their prediction performance on the test data (i.e. Monte Carlo cross validation). 544 GEUVADIS data. The GEUVADIS data 42 contains gene expression measurements for 545 465 individuals from five different populations: CEPH (CEU), Finns (FIN), British 546 (GBR), Toscani (TSI) and Yoruba (YRI). Following previous studies 65 , we focused only 547 on protein coding genes and lincRNAs that are annotated from GENCODE 66 (release 12). 548
We removed lowly expressed genes that have zero counts in at least half of the 549 individuals and obtained a final set of 15,810 genes. Afterwards, following previous 550 studies 67 , we performed PEER normalization to remove confounding effects and 551 unwanted variations. In order to remove potential population stratification, we quantile 552 normalized the gene expression measurements across individuals in each population to a 553 standard normal distribution, and then quantile normalized the gene expression 554 measurements to a standard normal distribution across individuals from all five 555 populations. In addition to the gene expression data, all individuals in GEUVADIS also 556 have their genotypes sequenced in the 1000 Genomes Project. Among the sequenced 557 genotypes, we filtered out SNPs that have a Hardy-Weinberg equilibrium (HWE) p-value 558 < 10 -4 , a genotype call rate < 95%, or an MAF < 0.01. We retained a total of 7,072,917 559 SNPs for analysis. We intersected these SNPs with imputed SNPs from WTCCC data 4 560 (see below; for the purpose of performing gene set tests) and kept a final set of 2,793,818 561 overlapping SNPs for analysis. Then, for each gene in turn, we obtained its cis-SNPs that 562 are located within either 100 kb upstream of the transcription start site (TSS) or 100 kb 563 downstream of the transcription end site (TES), resulting in an average of 175 cis-SNPs 564 per gene. 565 WTCCC data. The Wellcome Trust Case Control Consortium 4 (WTCCC) 1 data 566 consists of about 14,000 cases from seven common diseases and 2,938 shared controls. 567
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The cases include 1,963 individuals with type 1 diabetes (T1D), 1,748 individuals with 568
Crohn's disease (CD), 1,860 individuals with rheumatoid arthritis (RA), 1,868 569 individuals with bipolar disorder (BD), 1,924 individuals with type 2 diabetes (T2D), 570 1,926 individuals with coronary artery disease (CAD), and 1,952 individuals with 571 hypertension (HT). We obtained quality controlled genotypes from WTCCC and imputed 572 missing genotypes using BIMBAM 68 . We obtained a total of 458,868 SNPs shared 573 across all individuals. We then further imputed SNPs using the 1000 Genomes as the 574 reference panel with SHAPEIT and IMPUTE2 69 . We filtered out SNPs that have a HWE 575 p-value < 10 -4 , a genotype call rate < 95%, or an MAF < 0.01 to obtain a total of 576 2,793,818 imputed SNPs. For PrediXcan analysis 12 , as in the GEUVADIS data (see 577 above), we focused on the same 15,810 genes. As in 12 , we further restricted our 578 association analysis on a set of 4,343 genes that have a predictive R 2 above 0.01 by all 579 predictive methods. 580
Cattle data. The cattle data 17 consists of 5,024 samples and 42,551 SNPs after removing 581
SNPs that have a HWE p-value < 10 -4 , a genotype call rate < 95%, or an MAF < 0.01. 582
For the remaining SNPs, we imputed missing genotypes with the estimated mean 583 genotype of that SNP. We analyzed three traits: milk fat percentage (MFP), milk yield 584 (MY), and somatic cell score (SCS). All phenotypes were quantile normalized to a 585 standard normal distribution before analysis. 586
Maize data. The maize data 15 consists of 2,267 inbred accessions and 98,385 SNPs after 587 removing SNPs that have a HWE p-value < 10 -4 , a genotype call rate < 95%, or an MAF 588 < 0.01. For the remaining SNPs, we imputed missing genotypes with the estimated mean 589 genotype of that SNP. We used the growing degree days (GDD) to silking as the 590 phenotype in genomic selection. GDD was calculated using climate data from weather 591 stations located near the farms 15 , and was quantile normalized to a standard normal 592 distribution before analysis. 593
Framingham heart study data. The Framingham heart study (FHS) data contains 594 genotype data on 6,950 individuals and 394,174 SNPs. We filtered out SNPs that have a 595 HWE p-value < 10 -4 , a genotype call rate < 95%, or an MAF < 0.01 to obtain a final set 596 of 387,741 SNPs. For these SNPs, we imputed missing genotypes with the estimated 597 23/43 mean genotype of that SNP. We performed analysis on eight traits: five commonly used 598 plasma traits that include low-density lipoprotein (LDL) cholesterol, glucose (GLU), 599 high-density lipoprotein (HDL) cholesterol, total cholesterol (TC), and triglycerides (TG); 600 and three anthropometric traits that include height, weight, and body mass index (BMI). 601
Each trait was quantile normalized to a standard normal distribution before analysis. 602
Note that the FHS data is a family-based study where individuals are genetically related. 603
To tease apart the influence of individual relatedness on prediction performance among 604 methods, we also divided the samples in FHS into two separate data sets with different 605 levels of relatedness. Specifically, we first used genotypes to compute the genome-wide output parameter estimates. Therefore, for the PrediXcan analysis, we first merged the 631 GEUVADIS and WTCCC files for every gene, labeled WTCCC individuals as having 632 missing phenotypes, and then ran rjMCMC on these files to obtained predicted gene 633 expression values using the WTCCC genotype data. The same strategy was also applied 634 to perform cross-validation prediction between D1 and D2 sub data sets in FHS. For gene 635 expression prediction and PrediXcan analysis, following the original PrediXcan paper 12 , 636 we also used Elastic Net (ENET) 44 , which is implemented in the R package glmnet 637 (version 1.9-5). For ENET, following 12 , we set one penalty parameter (i.e. α ) to be 0.5 638 and selected the other one using 100-fold cross validation in the training data. 639 Data availability. No data were generated in the present study. The GEUVADIS gene 640 expression data is publicly available at http://www.geuvadis.org. The genotype data from 641 the 1000 genomes project is publicly available at http://www.internationalgenome.org. 642
The WTCCC genotype and phenotype data is publicly available at 643 https://www.wtccc.org.uk. The genotype and phenotype data from the cattle and maize 644 studies are available from the authors upon reasonable request and with permission of 645 The table lists the number of genes passing the genome-wide significance threshold via 1123
